scout
|Videos|May 22, 2017

Results for Pembrolizumab as a First-Line Therapy for Advanced Urothelial Carcinoma

Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discussed results of the KEYNOTE-052 study of pembrolizumab as a first-line therapy for patients with cisplatin-ineligible advanced urothelial cancer.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME